

	API	Develco-Code	Indication	Formulation	Strengths (mg)	Reference Product	Regulatory Status	Shelf life
ADHD	Methylphenidate	MCR / MCE ⁺	ADHD	PR tablet (MUPS)	18 - 27 - 36 - 45 ⁺ - 54 - 72 ⁺	Concerta® Johnson & Johnson	Approved in the EU	MCR: 48 months
		MKT	ADHD	PR capsule	5 - 10 - 20 - 30 - 40 - 50 - 60	Medikinet® retard Medice	Approved in the EU	ongoing: 24 months expected at launch
		MQS	ADHD	PR capsule	10 - 20 - 30 - 40 - 50 - 60	Ritalin® LA Novartis	Approved in the EU, available for US and Canada	36 months
		MEQ	ADHD	PR capsule	10 - 20 - 30 - 40 - 50 - 60	Equasym® Shire/Takeda	Approved in the EU	36 months
	Dexmethylphenidate	DXM	ADHD	PR capsule	5 - 10 - 15 - 20 - 25 - 30 - 40	Focalin XR® Novartis	Development ongoing	TBD
Pain / Substitution	Hydromorphone	HIR	Pain	IR capsule	1.3 - 2.6	Palladone® Mundipharma	Approved in the EU	36 months
		HTD [#]	Pain	PR tablet (MUPS, twice-daily)	4 - 8 - 16 - 24	Palladone® PR Mundipharma	Approved in the EU	48 months
		HOD*	Pain	PR tablet (MUPS, once-daily)	4 - 8 - 16 - 32	Jurnista® Janssen-Cilag/Develco*	Approved in the EU, available for all markets except DE, ES, PT	48 months
	Levomethadone	LIR	Pain / Substitution	IR tablet	2.5 - 5 - 7.5 - 20 - 30 - 40	L-Polamidon®Sandoz	Approved in the EU	48 months
	Oxycodone	OOD*	Pain	PR tablet (MUPS, once-daily)	10 - 20 - 40 - 80	Oxygesic® twice-daily Mundipharma/Develco*	Approved in the EU	48 months
	Oxycodone / Naloxone	ONA / OLE ⁺	Pain	PR tablet	5/2.5 - 10/5 - 20/10 - 30/15 40/20 - 60/30 ⁺ - 80/40 ⁺	Targin® Mundipharma	Approved in the EU	36 months
	Tapentadol	TTT	Pain	PR tablet (twice-daily)	25 - 50 - 100 - 150 - 200 - 250	Palexia® PR Grünenthal	Approved in the EU	36 months
		TIR	Pain	IR tablet	50 - 75 - 100	Palexia® IR Grünenthal	Registration ongoing	ongoing: 24 months expected at launch
		TTD	Pain	PR capsule (twice daily)	25 - 50 - 100 - 150 - 200 - 250	Palexia® PR Grünenthal	Approved in the UK	24 months
		TOD	Pain	PR tablet (once-daily)	50 - 500	Palexia® PR twice daily Grünenthal	Development ongoing	TBD
	Morphine	MRS	Substitution	PR capsule	60 - 100 - 200	Substitol® Mundipharma	Development ongoing	TBD
Epilepsy / Parkinson's	Brivaracetam	BOD*	Epilepsy	PR capsule (once-daily)	50 - 100 - 200	Briviact® UCB / Develco*	Development ongoing	TBD
	Oxcarbazepine	OXO	Epilepsy	XR tablet - (once-daily)	600	Oxtellar XR® (US) Supernus	Development ongoing	TBD
	Piribedil	PBD	Parkinson's	XR tablet (twice-daily)	50	Trivastal® Retard Servier	Development ongoing	TBD
⁺ differentiated strength [#] differentiated dosage form * Value Added Medicine (Europe)								